Answers are grounded in this paper and cite their sources.
OBJECTIVE: Self-limited focal epilepsies (SeLFEs) of childhood, including self-limited epilepsy with centrotemporal spikes (SeLECTS), self-limited epilepsy with autonomic seizures (SeLEAS), childhood occipital visual epilepsy (COVE), and photosensitive occipital lobe epilepsy (POLE), are common pediatric epilepsy syndromes with heterogeneous clinical management. We performed a scoping review to synthesize evidence regarding the use, effectiveness, safety, and discontinuation of antiseizure medications (ASMs) in children with SeLFEs. METHODS: Nine databases were searched from inception to January 2026. Eligible studies included original research reporting ASM-related outcomes in children with SeLFEs. PRISMA-ScR (Preferred Reporting Items of Systematic Reviews and Meta-Analyses, extension for scoping reviews) guidance was followed. RESULTS: Sixty-two studies met eligibility criteria, including 11 randomized controlled trials (RCTs). Most studies evaluated SeLECTS (6171 participants), whereas substantially fewer investigated SeLEAS (n = 348), COVE (n = 91), or POLE (n = 26). Evidence was highly heterogeneous and consisted predominantly of retrospective observational studies. In SeLECTS, reported 12-month seizure freedom rates after ASM treatment were approximately 72% across studies, although estimates varied considerably. Evidence for SeLEAS, COVE, and POLE was limited and derived mainly from small retrospective cohorts with heterogeneous methodologies and outcome definitions. Failure of first-line ASM therapy occurred in approximately 30% of patients. Adverse events were reported in approximately 22% of treated children and infrequently led to treatment discontinuation. RCTs generally reported similar seizure outcomes across multiple ASMs, although many trials were limited by small sample sizes and open-label designs. SIGNIFICANCE: Current evidence suggests that children with SeLFEs often achieve seizure control with ASM treatment and that adverse effects are generally manageable. However, the overall certainty of evidence remains limited because of methodological heterogeneity, predominance of retrospective studies, and limited randomized data. Important evidence gaps remain regarding the need for ASM treatment, optimal treatment duration, and timing of medication withdrawal.
No takes yet. Share an insight, caveat, or question.
Coan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: